Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imidapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidapril SCHEMBL22492310 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL6516062 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL683273 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7354516 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL11014327 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL34098 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL34099 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL12894585 | 1.00 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7294155 | 0.99 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL136722 | 0.99 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029734-A1 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-6610682-B2 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | SANKYO COMPANY, LIMITED (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020013308-A1 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | SANKYO COMPANY LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| EP-1175902-A1 | Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis | Sankyo Company Limited (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0930076-A1 | MEDICINAL COMPOSITIONS | SANKYO COMPANY LIMITED (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013308-A1 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | AGTR1, AGTR2, ACE | ACE 3/4885LMNA 543/4885ABCB11 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.